dr. tripathy discusses impact of t-dm1 in her2 breast cancer
Published 5 years ago • 396 plays • Length 1:07Download video MP4
Download video MP3
Similar videos
-
1:09
dr. tripathy on trastuzumab deruxtecan versus t-dm1 in her2-expressing breast cancers
-
1:38
dr. debu tripathy discusses the updated emilia trial results for t-dm1
-
1:10
dr. tripathy on targeting her2 in breast cancer
-
0:51
dr. tripathy discusses immunotherapy in her2 breast cancer
-
1:54
dr. tripathy discusses pertuzumab in her2 breast cancer
-
3:27
dr. tripathy on neoadjuvant treatment strategies in her2 breast cancer
-
2:00
dr. esteva discusses t-dm1 in her2-positive breast cancer
-
13:08
exploring tucatinib's impact on her2-positive breast cancer
-
4:33
upfront t-dm1 in her2-positive breast cancer
-
9:38
role of t-dm1 in her2-positive metastatic breast cancer
-
1:43
dr. tripathy discusses her2 targeted therapies
-
1:28
dr. tripathy on immunotherapy potential in her2-positive breast cancer
-
1:06
dr. tripathy on determining the best her2 targeted therapy
-
1:57
dr. tripathy discusses the averel bevacizumab trial results
-
1:14
dr. cheng on the role of t-dm1 in her2 breast cancer
-
1:21
dr. louis weiner discusses the t-dm1 emilia trial for her2-positive breast cancer
-
1:08
dr. tripathy on standard and emerging treatment advances for her2 breast cancer
-
1:20
dr. tripathy discusses neratinib in her2 breast cancer
-
0:45
dr. tripathy discusses breast cancer gene profiling